Clinical trials: Intraductal Papillary Mucinous Neoplasm
Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma
Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery
This randomized phase II-R/III trial studies gemcitabine hydrochloride with or without erlotinib hydrochloride followed by the same chemotherapy regimen with or without radiation therapy and capecitabine or fluorouracil in…
- Conditions
- Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Pancreatic Intraductal Papillary-Mucinous Neoplasm, Stage I Pancreatic Cancer AJCC v6 and v7
- Trial name
- NCT01013649
- Testing
- 3-Dimensional Conformal Radiation Therapy, Biospecimen Collection, Capecitabine
- Where
- 689 sites in United States, Belgium and 2 more
- Volunteers
- 546 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Cyst
Contrast Enhanced Ultrasound and Molecular Analysis in the Diagnosis of Pancreatic Cyst
This study evaluates the use of contrast-enhanced harmonic endoscopic ultrasound (CH-EUS) and cyst fluid molecular analysis in the differential diagnosis of pancreatic cysts and the detection of malignancy.
- Trial name
- NCT03740360
- Where
- Spain
- Volunteers
- 36 people
- Sponsor
- Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
Pancreatic Cyst
Hyperpolarized C Pyruvate Magnetic Resonance Imaging, and Blood-Based Biomarkers for Early Detection of Pancreatic Adenocarcinoma in Patients With Intraductal Papillary Mucinous Neoplasms
The purpose of this study is for researchers to find ways of detecting pancreatic ductal adenocarcinoma/PDAC early to avoid the invasive procedure of surgery.
- Trial name
- NCT06305728
- Testing
- 89Zr-DFO-HuMab-5B1 immunoPET, HP MRI, Blood assay
- Where
- 8 sites in United States
- Volunteers
- 25 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Pancreas Cyst
DNA-mutation Analysis in Cyst Fluid of Suspected Intraductal Papillary Mucinous Neoplasia of the Pancreas
Diagnostic tools are needed to identify mucinous cysts for further evaluation or follow-up respectively to identify cysts with HGD or invasive cancer at an early stage for surgical resection.
- Trial name
- NCT03820531
- Testing
- Next Generation Sequencing, CEA and lipase, Cytology
- Where
- Germany
- Volunteers
- 150 people
- Sponsor
- Theresienkrankenhaus und St. Hedwig-Klinik GmbH
Pancreatic Cancer, Intraductal Papillary Mucinous Neoplasm
Artificial Intelligence-powered Low-Dose Computed Tomography for Screening of Pancreatic Cancer
Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, with early diagnosis crucial for improving survival. Due to the absence of effective screening methods, most patients are diagnosed at advanced stages.
- Conditions
- Pancreatic Cancer, Intraductal Papillary Mucinous Neoplasm, High-grade Pancreatic Intraepithelial Neoplasia, PDAC - Pancreatic Ductal Adenocarcinoma
- Trial name
- AI-LDCT-PC (NCT07117045)
- Testing
- Diagnostic Evaluation for Positive AI Findings
- Where
- 5 sites in China
- Volunteers
- 400,000 people, healthy volunteers welcome
- Sponsor
- Changhai Hospital
Pancreas Cancer
Pancreas Cancer Surveillance Using an Abbreviated MRI
This study aims to establish a prospective cohort of developing pancreas cancer and surveillance MRI protocol. With the focused surveillance protocol, we perform surveillance for pancreas cancer for five years to estimate the…
- Trial name
- NCT04592393
- Testing
- Abbreviated PB MRI, Gene mutation test, Conventional follow-up
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Seoul National University Hospital
Pancreatic Cancer, Neoplasm
Family and Personal History of Malignancy in Intraductal Papillary Mucinous Neoplasm (IPMN)
This is a retrospective observational study to determine the proportion of patients with a family history of pancreatic cancer and other malignancies among patients who have intraductal papillary mucinous neoplasm (IPMN).
- Trial name
- NCT01104077
- Where
- United States
- Volunteers
- 277 people
- Sponsor
- Columbia University
Pancreatic Ductal Adenocarcinoma (PDAC), Intraductal Papillary Mucinous Neoplasm of Pancreas
Predictive Biomarkers for Early Diagnosis of Pancreatic Ductal Adenocarcinoma (PDAC)
Pancreatic ductal adenocarcinoma (PDAC) is one of the cancers with the poorest prognosis and is often diagnosed at an advanced stage, resulting in very low 5-year survival rates.
- Conditions
- Pancreatic Ductal Adenocarcinoma (PDAC), Intraductal Papillary Mucinous Neoplasm of Pancreas, Pancreatic Intraepithelial Neoplasia
- Trial name
- B-PDAC (NCT07709052)
- Volunteers
- 180 people
- Sponsor
- Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis
Breast Cancer, Long-term Effects Secondary to Cancer Therapy in Adults
Partial Breast Radiation Therapy in Treating Women Undergoing Breast Conservation Therapy for Early-Stage Breast Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. PURPOSE: This clinical trial is studying the side effects of partial breast radiation therapy and how well it works in treating women undergoing breast…
- Conditions
- Breast Cancer, Long-term Effects Secondary to Cancer Therapy in Adults, Skin Reactions Secondary to Radiation Therapy
- Trial name
- NCT00599989
- Testing
- adjuvant therapy, conventional surgery, 3-dimensional conformal radiation therapy
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Intraductal Papillary Mucinous Neoplasm of Pancreas, Pancreatic Cyst
Endocrine, Metabolic, Inflammatory Biomarkers to Identify Highgrade Dysplasia/invasive Carcinoma in Patients with IPMN of the Pancreas
Under the hypotheses that a more accurate patients selection could limit the problem of overtreatment and that benign intraductal papillary mucinous neoplasms (IPMN) have a distinguishable Endocrine/Metabolic/Inflammatory (EMI)…
- Trial name
- EMI-IPMN (NCT06706700)
- Where
- Italy
- Volunteers
- 586 people
- Sponsor
- IRCCS San Raffaele
Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma
AI-powered Early Detection for Pancreatic Cancer Via Non-contrast CT in Opportunistic Screening Cohort
Pancreatic ductal adenocarcinoma (PDAC) remains a therapeutic challenge with 5-year survival rates of 13%, primarily attributable to advanced-stage diagnosis (AJCC Stage III/IV in >80% of cases).
- Conditions
- Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Pancreatic Intraepithelial Neoplasias, Intraductal Papillary Mucinous Neoplasm
- Trial name
- AI-PANC (NCT06638866)
- Testing
- PDAC, Pancreatic precursor lesions
- Where
- 3 sites in China
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Changhai Hospital
McCune-Albright Syndrome, Fibrous Dysplasia
Characterization of Diabetes Mellitus in Fibrous Dysplasia/McCune-Albright Syndrome
The investigators' objective is to understand the pathogenesis of diabetes mellitus in Fibrous dysplasia/McCune-Albright syndrome (FD/MAS) by: 1) establishing the contributions of insulin resistance versus impaired insulin…
- Conditions
- McCune-Albright Syndrome, Fibrous Dysplasia, Intraductal Papillary Mucinous Neoplasm, Diabetes Mellitus
- Trial name
- NCT03520153
- Testing
- Hyperinsulinemic Euglycemic Clamp and 2H20, Hyperglycemic Clamp, Oral Glucose Tolerance Test
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Yale University